Because a given receptor must display at least moderately strong expression intensity (i.e., IRS ≥6) to be clinically useful as a target structure, our results indicate that very few patients with thyroid cancer would likely benefit from SST- or CXCR4-based diagnostics or therapy. This evidence concerns the gene CXCR4 and thyroid gland carcinoma.